A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 4, 2008, Pages 579-585

  Clamp, A R ^a   Schoffski P ^b   Valle, J W ^a   Wilson, R H ^c   Marreaud, S ^d   Govaerts, A S ^d   Debois, M ^d   Lacombe, D ^d   Twelves, C ^d   Chick, J ^e   Jayson, G C ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d EORTC DATA CENTER   (Belgium)

^e OSI Pharmaceuticals   (United Kingdom)

Author keywords

Colorectal carcinoma; OSI 7904L; Oxaliplatin; Phase I; Thymidylate synthase

Indexed keywords

OSI 7904L; OXALIPLATIN; THYMIDYLATE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HEMATOLOGIC DISEASE; HUMAN; MALE; MOTOR NEUROPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ORAL MUCOSITIS; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SKIN EXFOLIATION; SKIN TOXICITY; STOMATITIS; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; GLUTARATES; HUMANS; ISOINDOLES; LIPOSOMES; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; QUINAZOLINES; THYMIDYLATE SYNTHASE;

EID: 38049033372     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0509-5     Document Type: Article

References (26)

1. Colorectal Cancer Collaborative Group (2000) Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ 321:531-535
2. Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multi-centre randomized trial. Lancet 355:1041-1047
3. De Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment for metastatic colorectal cancer. J Clin Oncol 18:2938-2947
4. Tournigand C, Andre T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229-237
5. Longley DB, Harkin DP, Johnston PG (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330-338
6. De Gramont A, Bosset JF, Milan C et al (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15:808-815
7. Van Cutsem E, Twelves C, Cassidy J et al (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 19:4097-4106
8. Douillard JY, Hoff PM, Skillings JR et al (2002) Multicenter phase III study of uracil/ tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3605-3616
9. Desjardins J, Emerson DL, Colagiovanni DB, Abbott E, Brown EN, Drolet DW (2004) Pharmacokinetics, safety and efficacy of a liposome encapsulated thymidylate synthase inhibitor, OSI-7904L [(S)-2-[5-[1,2-dihydro-3-methyl-1- oxobenzo[f]quinazolin-9-yl)methyl]amino-1-oxo-2-isoindolynl]-glutaric acid] in mice. J Pharmacol Exp Ther 309:894-902
10. Beutel G, Glen H, Schöffski P et al (2005) Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors. Clin Cancer Res 11:5487-5495
11. Winski S, Nilsson C, Brown E et al (2002) In vivo antitumor efficacy of liposomal OSI-7904L in human tumor xenografts. NCI-EORTC-AACR Molecular targets and cancer therapeutics meeting, 2002 Abstract 119
12. Pendyala L, Leichman CG, Clark K et al (2001) Oxaliplatin influences the intra-tumoral expression of γ-glutamylcysteine synthetase and thymidylate synthase genes in patients with esophagus cancer. Proc Am Soc Clin Oncol 20, 351a
13. Kawakami K, Omura K, Kanehira E et al (1999) Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 19:3249-3252
14. Chen J, Hunter DJ, Stampfer MJ et al (2003) Polymorphism in the thymidylate synthase promoter enhancer region modifies risk and survival of colorectal cancer. Cancer Epidemiol Biomarkers Prev 12:958-962
15. Mandola MV, Stoehlmacher J, Muller-Weeks S et al (2003) A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 63:2898-2904
16. Morganti M, Ciantelli M, Giglioni B et al (2005) Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers. Eur J Cancer 41:2176-2183
17. Gurubhagavatula S, Liu G, Park S et al (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22:2594-2601
18. Spitz MR, Wu X, Wang Y et al (2001) Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 61:1354-1357
19. Stoehlmacher J, Park DJ, Zhang W et al (2004) A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91:344-354
20. Cancer Therapy Evaluation Programme (2003) Common Terminology Criteria for Adverse Events, Version 3.0. DCTD, NCI, NIH, DHHS. December 12 2003. ( http://www.ctep.cancer.gov/reporting/ctc_v3.0 )
21. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
22. Falk SJ, Anthoney A, Eatock M et al (2006) Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. Br J Cancer 95:450-456
23. Graham MA, Lockwood GF, Greenslade D et al (2000) Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 6:1205-1218
24. Extra JM, Espie M, Calvo F et al (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25:299-303
25. Maindrault-Goebel F, de Gramont A, Louvet C et al (2001) High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 37:1000-1005
26. Ford HER, Mitchell F, Cunningham D et al (2002) Patterns of elevation of plasma 2′-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331. Clin Cancer Res 8:103-109